URGN - ユ―ロジェン・ファ―マ (UroGen Pharma Ltd.)

URGNのニュース

   Mark Schoenberg Sells 1,076 Shares of UroGen Pharma Ltd. (NASDAQ:URGN) Stock  2021/02/04 11:27:20 Watchlist News
UroGen Pharma Ltd. (NASDAQ:URGN) insider Mark Schoenberg sold 1,076 shares of the firm’s stock in a transaction dated Sunday, January 31st. The shares were sold at an average price of $22.07, for a total transaction of $23,747.32. Following the completion of the sale, the insider now owns 21,831 shares in the company, valued at $481,810.17. […]
   Tesla Stock – Urogen Pharma (URGN) CEO Elizabeth A. Barrett Purchased $185,000 of Shares  2020/12/16 02:57:05 Fintech Zoom
Tesla Stock - Urogen Pharma (URGN) CEO Elizabeth A. Barrett Purchased $185,000 of Shares -
   Urogen Pharma Ltd (NASDAQ:URGN) Given Consensus Rating of “Hold” by Analysts  2020/10/25 00:28:41 US Banking News
Urogen Pharma Ltd (NASDAQ:URGN) has received an average recommendation of “Buy” from the nine research firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and five have given a buy recommendation to the company. The average 1 year price objective […]
   Urogen Pharma Ltd (NASDAQ:URGN) Receives Average Rating of “Hold” from Analysts  2020/10/24 22:28:47 Daily Political
Shares of Urogen Pharma Ltd (NASDAQ:URGN) have received a consensus rating of “Buy” from the nine analysts that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating on the company. The average 1-year price […]
   UroGen Pharma : Reports Second Quarter 2020 Financial Results and Recent Corporate Developments | MarketScreener  2020/08/10 12:04:04 MarketScreener
Received U.S. FDA Approval of Jelmyto®, the First and Only Non-Surgical Treatment for Patients with Low-Grade Upper Tract Urothelial Cancer Successfully Commenced Launch of Jelmyto on June 1st… | August 10, 2020
   Urogen Pharma Ltd (NASDAQ:URGN) Given Consensus Rating of “Hold” by Analysts  2020/10/25 00:28:41 US Banking News
Urogen Pharma Ltd (NASDAQ:URGN) has received an average recommendation of “Buy” from the nine research firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and five have given a buy recommendation to the company. The average 1 year price objective […]
   Urogen Pharma Ltd (NASDAQ:URGN) Receives Average Rating of “Hold” from Analysts  2020/10/24 22:28:47 Daily Political
Shares of Urogen Pharma Ltd (NASDAQ:URGN) have received a consensus rating of “Buy” from the nine analysts that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating on the company. The average 1-year price […]
   UroGen Pharma : Reports Second Quarter 2020 Financial Results and Recent Corporate Developments | MarketScreener  2020/08/10 12:04:04 MarketScreener
Received U.S. FDA Approval of Jelmyto®, the First and Only Non-Surgical Treatment for Patients with Low-Grade Upper Tract Urothelial Cancer Successfully Commenced Launch of Jelmyto on June 1st… | August 10, 2020
   UroGen Pharma to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020  2020/08/03 12:00:00 Business Wire
UroGen Pharma Ltd. (Nasdaq:URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases
   UroGen Pharma to Present at Jefferies Virtual Healthcare Conference  2020/06/01 12:00:00 Business Wire
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that Liz Barrett, President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020, at 3:30 PM Eastern Time. A live audio webcast of the event will be available on the Investors section of UroGen's website, www.urogen
   Urogen Pharma Ltd (NASDAQ:URGN) Given Consensus Rating of “Hold” by Analysts  2020/10/25 00:28:41 US Banking News
Urogen Pharma Ltd (NASDAQ:URGN) has received an average recommendation of “Buy” from the nine research firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and five have given a buy recommendation to the company. The average 1 year price objective […]
   Urogen Pharma Ltd (NASDAQ:URGN) Receives Average Rating of “Hold” from Analysts  2020/10/24 22:28:47 Daily Political
Shares of Urogen Pharma Ltd (NASDAQ:URGN) have received a consensus rating of “Buy” from the nine analysts that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating on the company. The average 1-year price […]
   UroGen Pharma : Reports Second Quarter 2020 Financial Results and Recent Corporate Developments | MarketScreener  2020/08/10 12:04:04 MarketScreener
Received U.S. FDA Approval of Jelmyto®, the First and Only Non-Surgical Treatment for Patients with Low-Grade Upper Tract Urothelial Cancer Successfully Commenced Launch of Jelmyto on June 1st… | August 10, 2020
   UroGen Pharma to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020  2020/08/03 12:00:00 Business Wire
UroGen Pharma Ltd. (Nasdaq:URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases
   UroGen Pharma to Present at Jefferies Virtual Healthcare Conference  2020/06/01 12:00:00 Business Wire
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that Liz Barrett, President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020, at 3:30 PM Eastern Time. A live audio webcast of the event will be available on the Investors section of UroGen's website, www.urogen

calendar